Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Diabetes. Dec 15, 2013; 4(6): 365-371
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.365
Table 1 Baseline characteristics of patients who completed the study
Switch to the highest dose of rosuvastatinAdd-on-statin ER-NA/LRPTAdd-on-statin micronised fenofibrateP
Sex (males/females) 32 (17/15) 26 (14/12)32 (16/16)NS
Age (yr)62 ± 1058 ± 1459 ± 12NS
Hypertension17 (53)14 (54)16 (50)NS
Diabetes mellitus6 (19)6 (23)6 (19)NS
Metabolic syndrome117 (53)15 (58)18 (56)NS
Smoking10 (31)9 (35)9 (28)NS
BMI (kg/m2)29.1 ± 2.529.1 ± 3.128.8 ± 3.2NS
TCNS
(mg/dL)205 ± 40200 ± 42200 ± 37
(mmol/L)5.5 ± 15.2 ± 1.15.2 ± 1
TriglyceridesNS
(mg/dL)190 (173-210) 213 (190-254)218 (189-260)
(mmol/L)2.2 (2.0-2.4) 2.4 (2.2-2.9)2.5 (2.1-2.9)
HDL-CNS
(mg/dL)50 ± 1047 ± 1145 ± 9
(mmol/L)1.3 ± 0.31.2 ± 0.31.1 ± 0.2
LDL-CNS
(mg/dL)116 ± 40109 ± 35112 ± 32
(mmol/L)3.2 ± 1.02.9 ± 0.92.9 ± 0.8
Non-HDL-CNS
(mg/dL)155 ± 40153 ± 37155 ± 34
(mmol/L)4.0 ± 1.04.0 ± 1.04.0 ± 0.9
Fasting plasma glucoseNS
(mg/dL)91 ± 2693 ± 1794 ± 10
(mmol/L)5.1 ± 1.45.2 ± 0.95.2 ± 0.6
HbA1c (%)6.1 ± 0.56.3 ± 1.16.1 ± 0.8NS
HOMA-IR index1.4 1.2-2.11.5 1.4-2.11.7 1.5-2.3NS
Medications at baseline
Aspirin9 (28)8 (31)7 (22)NS
Beta blockers9 (28)8 (31)9 (28)NS
HCTZ11 (34)10 (38)10 (31)NS
ACEIs/ARBs13 (41)11 (42)12 (38)NS
Calcium channel blockers8 (24)8 (31)10 (31)NS
Metformin6 (19)6 (23)5 (16)NS
Pioglitazone2 (7)1 (4)3 (9)NS
Sulfonylurea4 (13)3 (12)2 (6)NS
Atorvastatin 5-20 mg/d11 (34)9 (35)12 (38)NS
Simvastatin 10-40 mg/d11 (34)9 (35)9 (28)NS
Rosuvastatin 5-10 mg/d10 (31)8 (31)11 (34)NS